Watkins Tim 4

4 · Contineum Therapeutics, Inc. · Filed Jan 30, 2026

AI-generated summary of this filing

Updated Jan 30, 2026

Contineum (CTNM) CMO Tim Watkins Exercises Options & Sells Shares

What Happened

Tim Watkins, Chief Medical Officer & Head of Development at Contineum Therapeutics (CTNM), exercised 3,611 option shares on Jan 28, 2026 at $4.50 per share (cost = $16,250) and sold those 3,611 shares in open-market trades the same day for aggregate proceeds of about $51,188. The filing also reports a grant/award of 160,000 derivative shares on Jan 30, 2026 (no cash price reported).
The exercise + sale resulted in gross sale proceeds ~ $51,188 and an approximate spread (proceeds minus exercise cost) of $34,938 before taxes and fees. The 160,000-share award appears to be an equity grant (derivative) subject to vesting.

Key Details

Transaction dates: Jan 28, 2026 (exercise and sales); Jan 30, 2026 (award/grant).
Exercise: 3,611 shares @ $4.50 (total cost $16,250).
Sales: 2,800 shares @ weighted avg $14.09 (proceeds $39,441; prices ranged $13.44–$14.39 per F2); 811 shares @ weighted avg $14.48 (proceeds $11,747; prices ranged $14.45–$14.53 per F3). Total sale proceeds ≈ $51,188.
Award/Grant: 160,000 derivative shares reported 1/30/2026 at $0.00 (Form shows as acquisition of derivative).
Vesting notes: prior option vesting schedule noted — one-half vested Oct 28, 2025 with remainder vesting monthly (F4); options under the issuer’s 2024 Equity Incentive Plan vest over 48 months (F5).
Sales were effected under a pre-established 10b5-1 trading plan adopted Sept 23, 2025 (F1).
Shares owned after the transactions: not specified in the provided filing excerpt.
Filing timeliness: Form filed Jan 30, 2026 for transactions on Jan 28, 2026 — within the usual 2-business-day Form 4 reporting window (not marked late).

Context

This was a routine executive option exercise followed by open-market sales (common for option liquidity or tax/portfolio management). The sale was conducted under a 10b5-1 plan, which typically schedules trades in advance. The 160,000-share derivative award is subject to vesting per the plan footnotes; such grants are compensation, not an open-market purchase signal.

Form 4

Period: 2026-01-28

CMO & Head of Development

Transactions

Exercise/Conversion
Class A Common Stock
[F1]
2026-01-28$4.50/sh+3,611$16,250→ 3,611 total
Sale
Class A Common Stock
[F1][F2]
2026-01-28$14.09/sh−2,800$39,441→ 811 total
Sale
Class A Common Stock
[F1][F3]
2026-01-28$14.48/sh−811$11,747→ 0 total
Exercise/Conversion
Stock Option (right to buy)
[F1][F4]
2026-01-28−3,611→ 252,778 total
Exercise: $4.50Exp: 2035-04-27→ Class A Common Stock (3,611 underlying)
Award
Stock Option (right to buy)
[F5]
2026-01-30+160,000→ 160,000 total
Exercise: $14.26Exp: 2036-01-29→ Class A Common Stock (160,000 underlying)

Footnotes (5)

[F1]These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.44 to $14.39, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.45 to $14.53, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
[F4]One-half of the option shares vested on October 28, 2025, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service.
[F5]Options granted under the Issuer's 2024 Equity Incentive Plan. The options shares vest in equal monthly installments over 48 months, subject to the Reporting Person's continuous service.

Signature

/s/ Peter Slover, Attorney-in-Fact|2026-01-30

1 file